Establishing Efficacy of a New Experimental Treatment in the ‘Gold Standard’ Design

Provided that there are no ethical concerns, the comparison of an active drug with placebo in a randomized two-arm clinical trial provides the most convincing way to demonstrate the efficacy of a new experimental treatment. However, in a placebo-controlled clinical trial it is not sufficient to demonstrate merely a statistically significant treatment difference. Regulatory authorities strongly recommend to assess additionally whether the observed treatment difference is also of clinical relevance. The inherent issue is the necessity of the a priori definition of what constitutes a clinically relevant difference in efficacy. This problem can be solved in a three-arm study by including an active control group. We address the necessary conditions in the gold standard design which allow the claim of efficacy for the new treatment with particular focus on assay sensitivity.

[1]  A Specification of Treatment Difference in the Design of Clinical Trials with Active Controls , 1993 .

[2]  Iris Pigeot,et al.  Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. , 2003, Statistics in medicine.

[3]  John A. Lewis,et al.  Placebo-controlled trials and the Declaration of Helsinki , 2002, The Lancet.

[4]  R B D'Agostino,et al.  Multiple comparisons in over-the-counter drug clinical trials with both positive and placebo controls. , 1991, Statistics in medicine.

[5]  Comparisons between a new drug and active and placebo controls in an efficacy clinical trial. , 1992, Statistics in medicine.

[6]  G G Koch,et al.  Methodological advances and plans for improving regulatory success for confirmatory studies. , 1998, Statistics in medicine.

[7]  D. Brown.  ICH E9 guideline ‘Statistical principles for clinical trials’: a case study Response to A. Phillips and V. Haudiquet , 2003 .

[8]  S S Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues , 2000, Annals of Internal Medicine.

[9]  S. Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases , 2000, Annals of Internal Medicine.

[10]  Tie-Hua Ng,et al.  Choice of Delta in Equivalence Testing* , 2001 .

[11]  J Röhmel,et al.  Therapeutic equivalence investigations: statistical considerations. , 1998, Statistics in medicine.

[12]  L. Hothorn,et al.  Testing strategies in multi-dose experiments including active control. , 1998, Statistics in medicine.

[13]  Armin Koch,et al.  Hypothesis Testing in the “Gold Standard” Design for Proving the Efficacy of an Experimental Treatment Relative to Placebo and a Reference , 2004, Journal of biopharmaceutical statistics.